KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Gross Margin (2016 - 2026)

NovoCure's Gross Margin history spans 13 years, with the latest figure at 77.63% for Q1 2026.

  • On a quarterly basis, Gross Margin rose 249.0% to 77.63% in Q1 2026 year-over-year; TTM through Mar 2026 was 75.2%, a 196.0% decrease, with the full-year FY2025 number at 74.54%, down 280.0% from a year prior.
  • Gross Margin hit 77.63% in Q1 2026 for NovoCure, up from 75.82% in the prior quarter.
  • Over the last five years, Gross Margin for NVCR hit a ceiling of 79.84% in Q1 2022 and a floor of 73.01% in Q2 2023.
  • Historically, Gross Margin has averaged 76.38% across 5 years, with a median of 75.82% in 2025.
  • Biggest five-year swings in Gross Margin: plummeted -675bps in 2023 and later surged 394bps in 2024.
  • Tracing NVCR's Gross Margin over 5 years: stood at 77.51% in 2022, then decreased by -2bps to 75.67% in 2023, then rose by 5bps to 79.25% in 2024, then dropped by -4bps to 75.82% in 2025, then rose by 2bps to 77.63% in 2026.
  • Business Quant data shows Gross Margin for NVCR at 77.63% in Q1 2026, 75.82% in Q4 2025, and 73.25% in Q3 2025.